English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Introduction. Allogenic hematopoietic stem cell transplantation is the best   therapeutic option for the treatment of some inherited and acquired diseases   of the hematopoietic system as well as various hematological malignancies.   Material and Methods. The study was conducted as a retrospective analysis of   35 patients who underwent allogenic hematopoietic stem cell transplantation   at the Clinic of Hematology, Clinical Center of Vojvodina. Results. In a   group of 35 patients with median age 33 years, 13 patients had acute   myeloid leukemia, one patient had acute lymphoblastic leukemia, nine had   chronic myeloid leukemia, five had aplastic anemia, five myelodysplastic   syndrome, one had multiple myeloma and one had Ewing sarcoma. Nine patients   (26%) had an advanced, resistant disease at the time of transplantation. The   majority of patients had a matched related transplantation - 89% (31/35) -   three patients had syngeneic transplantation, and one patient had a   haploidentical transplantation. Out of 35 patients, 16 (45.7%) are alive.   The European Bone Marrow Transplantation score ?3 and the presence of   advanced disease at the time of transplant were unfavourable prognostic   factors for survival (p&lt;0.01). If we exclude the cases with advanced,   resistant disease at the time of transplantation, the probability of 5-year   survival rate was as follows: 100% in patients with aplastic anemia, 75% in   patients with acute leukemia, 34% in myelodysplastic syndrome, and 14% in   chronic myeloid leukemia patients. Conclusion. The outcome of allogeneic   hematopoietic stem cells transplantation in our patients is generally   comparable with previously reported results. The main prognostic factors for   survival were European Bone Marrow Transplantation risk score and disease   status at the time of transplantation.

Allogeneic hematopoietic stem cell transplantation at the Clinical Center of Vojvodina